SCHEMBL1339178

SCHEMBL1339178

CCn1nccc1-c1ccc2c(c1)c1cc(-c3ccc(Cl)cc3Cl)c(=O)n(C)c1n2COCC[Si](C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.36
▸ MARS1 P56192 1/20 0.35
▸ GABRA1 P14867 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ PTGER4 P35408 1/20 0.31
▸ RIPK2 O43353 1/20 0.31
▸ NOD2 Q9HC29 1/20 0.31
▸ CNR1 P21554 4/20 0.31
▸ CNR2 P34972 4/20 0.31
▸ ABL1 P00519 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339397 0.86 MARS1 (0.39) MARS1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339295 0.85 NPC1 (0.37) NPC1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1340547 0.84 NPC1 (0.36) NPC1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339497 0.84 NPC1 (0.37) NPC1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338115 0.82 NPC1 (0.48) NPC1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339158 0.81 MARS1 (0.36) MARS1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336974 0.79 CNR1 (0.38) PTGER4CNR1CNR2KDM4EALDH1A1
SCHEMBL1338705 0.77 MARS1 (0.42) MARS1GABRA1CNR1CNR2KDM4E
SCHEMBL1339163 0.77 NPC1 (0.43) NPC1CNR1CNR2ALDH1A1GAA
SCHEMBL1339165 0.77 NPC1 (0.43) NPC1CNR1CNR2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 NPC1 428/4885MARS1 2786/4885GABRA1 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback